This review is to describe synergistic effects of various combinations of dietary natural products including curcumin, quercetin, soybean isoflavones, silibinin, and EGCG that have potential for the treatment of prostate cancer. These data can provide valuable insights into the future rational design and development of synergistic and/or hybrid agents for potential treatment of prostate cancer.
ShimizuH, RossRK, BernsteinL, YataniR, HendersonBE, MackTM. (1991) Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. British Journal of Cancer, 63, 963–966;
2.
MillsPK, BeesonWL, PhillipsRL, FraserGE. (1989) Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer, 64, 598–604.
3.
ChenQ-H. (2015) Curcumin-based anti-prostate cancer agents. Anti-Cancer Agents in Medicinal Chemistry, 15, 138–156.
4.
AalinkeelR, BindukumarB, ReynoldsJL, SykesDE, MahajanSD, ChadhaKC, SchwartzSA. (2008) The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate (Hoboken, NJ, United States), 68, 1773–1789;
5.
SinghRP, RainaK, SharmaG, AgarwalR. (2008) Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clinical Cancer Research, 14, 7773–7780.
6.
PrasadS, TyagiAK, AggarwalBB. (2014) Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment golden spice. Cancer Research and Treatment, 46, 2–18.
7.
AliBH, MarrifH, NoureldayemSA, BakheitAO, BlundenG. (2006) Some biological properties of curcumin: a review. Natural Product Communications, 1, 509–521.
8.
van DieMD, BoneKM, WilliamsSG, PirottaMV. (2014) Soy and soy isoflavones in prostate cancer: a systematic review and meta-analysis of randomized controlled trials. BJU International, 113, E119–E130.
9.
IdeH, TokiwaS, SakamakiK, NishioK, IsotaniS, MutoS, HamaT, MasudaH, HorieS. (2010) Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate (Hoboken, NJ, United States), 70, 1127–1133.
10.
IdeH, YuJ, LuY, ChinaT, KumamotoT, KosekiT, MutoS, HorieS. (2011) Testosterone augments polyphenol-induced DNA damage response in prostate cancer cell line, LNCaP. Cancer Science, 102, 468–471.
11.
AdityaNP, ShimM, LeeI, LeeY, ImM-H, KoS. (2013) Curcumin and genistein coloaded nanostructured lipid carriers: in vitro digestion and antiprostate cancer activity. Journal of Agricultural and Food Chemistry, 61, 1878–1883.
12.
AdityaNP, ShimM, YangH, LeeY, KoS. (2014) Antiangiogenic effect of combined treatment with curcumin and genistein on human prostate cancer cell line. Journal of Functional Foods, 8, 204–213.
13.
HenningSM, WangP, HeberD. (2011) Chemopreventive effects of tea in prostate cancer: Green tea versus black tea. Molecular Nutrition & Food Research, 55, 905–920.
14.
WangP, WangB, ChungS, WuY, HenningSM, VadgamaJV. (2014) Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. RSC Advances, 4, 35242–35250.
15.
PittiRM, MarstersSA, RuppertS, DonahueCJ, MooreA, AshkenaziA. (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry, 271, 12687–12690.
16.
AshkenaziA, DixitVM. (1999) Apoptosis control by death and decoy receptors. Current Opinion in Cell Biology, 11, 255–260.
17.
DeebD, XuYX, JiangH, GaoX, JanakiramanN, ChapmanRA, GautamSC. (2003) Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. Molecular Cancer Therapeutics, 2, 95–103;
18.
DeebDD, JiangH, GaoX, DivineG, DulchavskySA, GautamSC. (2005) Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. Journal of Experimental Therapeutics and Oncology, 5, 81–91.
19.
AndrzejewskiT, DeebD, GaoX, DanylukA, ArbabAli S, DulchavskyScott A, GautamSubhash C. (2008) Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncology Research, 17, 257–267.
20.
DeebD, JiangH, GaoX, Al-HolouS, DanylukAL, DulchavskySA, GautamSC. (2007) Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-κB via inhibition of the prosurvival Akt signaling pathway. Journal of Pharmacology and Experimental Therapeutics, 321, 616–625.
21.
AdamV, EkbladM, SweeneyK, MuellerH, BuschKH, JohnsenCT, KangNR, LemoineNR, HalldenG. (2012) Synergistic and selective cancer cell killing mediated by the oncolytic adenoviral mutant AdΔΔ and dietary phytochemicals in prostate cancer models. Human Gene Therapy, 23, 1003–1015.
22.
LiJ, XiangST, ZhangQH, WuJJ, TangQ, ZhouJF, YangLJ, ChenZQ, HannSS. (2015) Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C. Journal of Experimental & Clinical Cancer Research, 34, 1–21.
23.
HourT-C, ChenJ, HuangC-Y, GuanJ-Y, LuS-H, PuY-S. (2002) Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21WAF1/CIP1 and C/EBPβ expressions and suppressing NF-κB activation. Prostate (New York, NY, United States), 51, 211–218.
24.
Cabrespine-FaugerasA, Bayet-RobertM, BayJ-O, CholletP, BarthomeufC. (2010) Possible benefits of curcumin regimen in combination with taxane chemotherapy for hormone-refractory prostate cancer treatment. Nutrition and Cancer, 62, 148–153.
25.
NayakBK, KrishnegowdaNK, GalindoCA, MeltzML, SwansonGP. (2010) Synergistic effect between curcumin (diferuloylmethane) and radiation on clonogenic cell death independent of p53 in prostate cancer cells. Journal of Cancer Science & Therapy, 2, 171–181.
26.
FirdousA, SharmilaG, BalakrishnanS, RajaSingh P, SuganyaS, SrinivasanN, ArunakaranJ. (2014) Quercetin, a natural dietary flavonoid, acts as a chemopreventive agent against prostate cancer in an in vivo model by inhibiting the EGFR signaling pathway. Food & Function, 5, 2632–2645;
WuK, NingZ, ZhouJ, WangB, FanJ, ZhuJ, GaoY, WangX, HsiehJ-T, HeD. (2014) 2′-Hydroxyflavanone inhibits prostate tumor growth through inactivation of AKT/STAT3 signaling and induction of cell apoptosis. Oncology reports, 32, 131–138.
29.
KumarR, VermaV, JainA, JainRK, MaikhuriJP, GuptaG. (2011) Synergistic chemoprotective mechanisms of dietary phytoestrogens in a select combination against prostate cancer. Journal of Nutritional Biochemistry, 22, 723–731.
30.
HsiehT-C, WuJM. (2009) Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Research, 29, 4025–4032.
31.
WangP, HeberD, HenningSM. (2012) Quercetin increased the antiproliferative activity of green tea polyphenol (-)-epigallocatechin gallate in prostate cancer cells. Nutrition and Cancer, 64, 580–587.
32.
TangS-N, SinghC, NallD, MeagherD, ShankarS, SrivastavaRK. (2010) The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. Journal of Molecular Signaling, 5, 14.
33.
HaddadAQ, VenkateswaranV, ViswanathanL, TeahanSJ, FleshnerNE, KlotzLH. (2006) Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate cancer and prostatic diseases, 9, 68–76;
34.
TsimplouliC, DemetzosC, Hadzopoulou-CladarasM, PantazisP, DimasK. (2012) In vitro activity of dietary flavonol congeners against human cancer cell lines. European Journal of Nutrition, 51, 181–190.
35.
CampbellJK, KingJL, HarmstonM, LilaMA, ErdmanJW. (2006) Synergistic effects of flavonoids on cell proliferation in Hepa-1c1c7 and LNCaP cancer cell lines. Journal of Food Science, 71, S358–S363;
36.
KnowlesLM, ZigrossiDA, TauberRA, HightowerC, MilnerJA. (2000) Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutrition and Cancer, 38, 116–122.
37.
WangP, PhanT, GordonD, ChungS, HenningSM, VadgamaJV. (2015) Arctigenin in combination with quercetin synergistically enhances the antiproliferative effect in prostate cancer cells. Molecular Nutrition & Food Research, 59, 250–261.
38.
LinC-C, HsuC-H, ChenJ, TsaiT-C, ChengA-L, PuY-S. (2001) A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Research, 21, 1385–1390.
39.
MaZ, NguyenTH, HuynhTH, DoPT, HuynhH. (2004) Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. International Journal of Oncology, 24, 1297–1304.
40.
KumarAP, GarciaGE, SlagaTJ. (2001) 2-Methoxyestradiol blocks cell-cycle progression at G2/M phase and inhibits growth of human prostate cancer cells. Molecular Carcinogenesis, 31, 111–124.
41.
SweeneyC, LiuG, YiannoutsosC, KolesarJ, HorvathD, StaabMJ, FifeK, ArmstrongV, TrestonA, SidorC, WildingG. (2005) A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clinical Cancer Research, 11, 6625–6633.
42.
WangG, SongL, WangH, XingN. (2013) Quercetin synergizes with 2-methoxyestradiol inhibiting cell growth and inducing apoptosis in human prostate cancer cells. Oncology Reports, 30, 357–63.
43.
KimYH, LeeDH, JeongJH, GuoZS, LeeYJ. (2008) Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway. Biochemical Pharmacology, 75, 1946–1958.
44.
JungYH, HeoJ, LeeYJ, KwonTK, KimYH. (2010) Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sciences, 86, 351–357.
45.
KimYH, LeeYJ. (2007) TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. Journal of Cellular Biochemistry, 100, 998–1009.
46.
XiongP, WangR, ZhangX, DeLaTorre E, LeonF, ZhangQ, ZhengS, WangG, ChenQ-H. (2015) Design, synthesis, and evaluation of genistein analogues as anti-cancer agents. Anti-Cancer Agents in Medicinal Chemistry, 15, 1197–1203.
47.
DongX, XuW, SikesRA, WuC. (2013) Combination of low dose of genistein and daidzein has synergistic preventive effects on isogenic human prostate cancer cells when compared with individual soy isoflavone. Food Chemistry, 141, 1923–1933.
48.
ZhouJ-R, YuL, ZhongY, BlackburnGL. (2003) Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. Journal of Nutrition, 133, 516–521.
49.
HaslamE. (2003) Thoughts on thearubigins. Phytochemistry, 64, 61–73.
50.
SakamotoK. (2000) Synergistic effects of thearubigin and genistein on human prostate tumor cell (PC-3) growth via cell cycle arrest. Cancer Letters (Shannon, Ireland), 151, 103–109.
51.
SchwartzGG, HulkaBS. (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Research, 10, 1307–1311.
52.
ZhuangS-H, BurnsteinKL. (1998) Antiproliferative effect of 1α,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology, 139, 1197–1207.
53.
RaoA, WoodruffRD, WadeWN, KuteTE, CramerSD. (2002) Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. Journal of Nutrition, 132, 3191–3194.
54.
RaoA, CoanA, WelshJ-E, BarclayWW, KoumenisC, CramerSD. (2004) Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Research, 64, 2143–2147.
55.
PlanchonSM, WuerzbergerS, FrydmanB, WitiakDT, HutsonP, ChurchDR, WildingG, BoothmanDA. (1995) β-Lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Research, 55, 3706–3711.
56.
Kumi-DiakaJ, Saddler-ShawnetteS, AllerA, BrownJ. (2004) Potential mechanism of phytochemical-induced apoptosis in human prostate adenocarcinoma cells: Therapeutic synergy in genistein and β-lapachone combination treatment. Cancer Cell International, 4, 5.
57.
ZhaoR, XiangN, DomannFE, ZhongW. (2009) Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells. Nutrition and Cancer, 61, 397–407.
58.
CorcoranC, RaniS, O'BrienK, O'NeillA, PrencipeM, SheikhR, WebbG, McDermottR, WatsonW, CrownJ, O'DriscollL. (2012) Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One, 7, e50999;
59.
YapTA, ZiviA, OmlinA, de BonoJS. (2011) The changing therapeutic landscape of castration-resistant prostate cancer. Nature Reviews Clinical Oncology, 8, 597–610.
60.
TorreLindsey A, BrayF, SiegelRebecca L, FerlayJ, Lortet-TieulentJ, JemalA. (2015) Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65, 87–108.
61.
BurichRA, HollandWS, VinallRL, TepperC, de Vere WhiteRW, MackPC. (2008) Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines. BJU International, 102, 1458–1466.
62.
KimN-C, GrafTN, SparacinoCM, WaniMC, WallME. (2003) Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Organic & Biomolecular Chemistry, 1, 1684–1689.
63.
FloraK, HahnM, RosenH, BennerK. (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. American Journal of Gastroenterology, 93, 139–143.
64.
ZiX, AgarwalR. (1999) Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proceedings of the National Academy of Sciences of the United States of America, 96, 7490–7495.
65.
ComelliMC, MengsU, SchneiderC, ProsdocimiM. (2007) Toward the definition of the mechanism of action of silymarin: activities related to cellular protection from toxic damage induced by chemotherapy. Integrative Cancer Therapies, 6, 120–129.
66.
WernekeU, EarlJ, SeydelC, HornO, CrichtonP, FannonD. (2004) Potential health risks of complementary alternative medicines in cancer patients. British Journal of Cancer, 90, 408–413.
67.
RainaK, AgarwalR. (2007) Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta pharmacologica Sinica, 28, 1466–1475.
68.
BellonSF, ColemanJH, LippardSJ. (1991) DNA unwinding produced by site-specific intrastrand crosslinks of the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry, 30, 8026–8035.
69.
DrelichmanA, OldfordJ, Al-SarrafM. (1985) Evaluation of cyclophosphamide, adriamycin, and cis-platinum (CAP) in patients with disseminated prostatic carcinoma. A phase II study. American Journal of Clinical Oncology, 8, 255–259.
70.
TrumpDL, MarshJC, KvolsLK, CitrinD, DavisTE, HahnRG, VoglSE. (1990) A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Investigational New Drugs, 8 Suppl 1, S91–S94.
71.
DhanalakshmiS, AgarwalP, GlodeLM, AgarwalR. (2003) Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. International Journal of Cancer, 106, 699–705.
72.
TyagiAK, SinghRP, AgarwalC, ChanDCF, AgarwalR, (2002) Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clinical Cancer Research, 8, 35123519.
73.
SinghRP, AgarwalR. (2004) Prostate cancer prevention by silibinin. Current Cancer Drug Targets, 4, 1–11.
74.
McKeageK. (2012) Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs, 72, 1559–1577.
75.
BahlA, MassonS, BirtleA, ChowdhuryS, de BonoJ. (2014) Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents. Cancer Treatment Reviews, 40, 170–177.
76.
GravisG, SalemN, BladouF, ViensP. (2007) Prostate cancer and chemotherapy. Bulletin du Cancer, 94 (Suppl. FMC, 6), F21–F28.
77.
FlaigTW, SuLJ, HarrisonG, AgarwalR, GlodeLM. (2007) Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. International Journal of Cancer, 120, 2028–2033.
78.
FujikiH, SuganumaM. (2012) Green tea: An effective synergist with anticancer drugs for tertiary cancer prevention. Cancer Letters (New York, NY, United States), 324, 119–125.
79.
AdhamiVM, MalikA, ZamanN, SarfarazS, SiddiquiIA, SyedDN, AfaqF, PashaFS, SaleemM, MukhtarH. (2007) Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clinical Cancer Research, 13, 1611–1619.
80.
Farivar-MohseniH, KandzariSJ, ZaslauS, RiggsDR, JacksonBJ, McFaddenDW. (2004) Synergistic effects of Cox-1 and –2 inhibition on bladder and prostate cancer in vitro. American Journal of Surgery, 188, 505–510;
81.
KamijoT, SatoT, NagatomiY, KitamuraT. (2001) Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. International Journal of Urology, 8, S35–S39.
82.
PlatzEA, RohrmannS, PearsonJD, CorradaMM, WatsonDJ, De MarzoAM, LandisPK, MetterEJ, CarterHB. (2005) Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore longitudinal study of aging. Cancer Epidemiology, Biomarkers & Prevention, 14, 390–396.
83.
AndrewsJ, DjakiewD, KrygierS, AndrewsP. (2002) Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemotherapy and Pharmacology, 50, 277–284.
84.
KimMH, ChungJ. (2007) Synergistic cell death by EGCG and ibuprofen in DU-145 prostate cancer cell line. Anticancer Research, 27, 3947–3956;
85.
KimMH. (2008) Protein phosphatase 1 activation and alternative splicing of Bcl-X and Mcl-1 by EGCG + ibuprofen. Journal pf Cellular Biochemistry, 104, 1491–1499.
86.
KobalkaAndrew J, KeckRick W, JankunJ. (2015) Synergistic anticancer activity of biologicals from green and black tea on DU 145 human prostate cancer cells. Central-European Journal of Immunology, 40, 1–4.
87.
GrayAL, StephensCA, BigelowRL, ColemanDT, CardelliJA. (2014) The polyphenols (-)-epigallocatechin-3-gallate and luteolin synergistically inhibit TGF-beta-induced myofibroblast phenotypes through RhoA and ERK inhibition. PLoS One, 9, e109208.
88.
LinY, ShiR, WangX, ShenH-M. (2008) Luteolin, a flavonoid with potential for cancer prevention and therapy. Current Cancer Drug Targets, 8, 634–646.
89.
ZhouQ, YanB, HuX, LiX-B, ZhangJ, FangJ. (2009) Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Molecular Cancer Therapeutics, 8, 1684–1691.
90.
SiddiquiIA, MalikA, AdhamiVM, AsimM, HafeezBB, SarfarazS, MukhtarH. (2008) Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene, 27, 2055–2063.
91.
StearnsMark E, WangM. (2011) Synergistic effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors. Translational Oncology, 4, 147–156.
92.
StearnsME, AmatangeloMD, VarmaD, SellC, GoodyearSM. (2010) Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies inhibition of metastatic tumor growth in severe combined immunodeficiency mice. American Journal of Pathology, 177, 3169–3179.
93.
HagenRM, ChedeaVS, MintoffCP, BowlerE, MorseHR, LadomeryMR. (2013) Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells. International Journal of Oncology, 43, 194–200.
94.
HuangL, KirschkeCatherine P, ZhangY. (2006) Decreased intracellular zinc in human tumorigenic prostate epithelial cells: a possible role in prostate cancer progression. Cancer Cell International, 6, 10.
95.
SunS-l, HeG-Q, YuH-N, YangJ-G, BorthakurD, ZhangL-C, ShenS-R, DasUN. (2008) Free Zn2+ enhances inhibitory effects of EGCG on the growth of PC-3 cells. Molecular Nutrition & Food Research, 52, 465–471.
